Abstract 16356: Hyperuricemia is an Independent Risk Factor for Cardiovascular Disease; A Sub-Analysis for REAL-CAD Study

IntroductionREAL-CAD study showed that high-dose (4 mg/d) compared with low-dose (1 mg/d) pitavastatin therapy significantly reduced cardiovascular events in patients with stable coronary artery disease (CAD).HypothesisWe hypothesized that high-dose statin reduced serum uric acid levels compared with low-dose statin, which affected the main results.MethodsThis study retrospectively analyzed the REAL-CAD database of 13,054 patients with stable CAD. We compared the levels of serum uric acid change between high-dose statin and low-dose statin 6 months later from study onset. Moreover, we checked if hyperuricemia, defined as >7.0 mg/dL in men and ≥6.0 mg/dL in women, causes cardiovascular events. We calculated hazard ratio (HR) of hyperuricemia for cardiovascular events after multivariable adjustments with age, sex, body mass index, smoking habits, diabetes, hypertension, chronic kidney disease, LDL-cholesterol, high-sense CRP (hs-CRP), white blood cell (WBC), and hyperuricemia.ResultsThe full analysis population consisted of 12,413 Japanese patients (68.1±8.3 years old, 82.6% men). Of those, 9,673 patients at the baseline and 9,698 patients at 6 months later from study onset had checked their serum uric acid levels. High-dose group showed significantly larger serum uric acid change over 6 months than low-dose group (-0.1505 mg/dL versus -0.0046 mg/dL, P